Natera, Inc. (NASDAQ:NTRA) Shares Bought by Moss Adams Wealth Advisors LLC

Moss Adams Wealth Advisors LLC lifted its position in shares of Natera, Inc. (NASDAQ:NTRA) by 5.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,646 shares of the medical research company’s stock after acquiring an additional 135 shares during the period. Moss Adams Wealth Advisors LLC’s holdings in Natera were worth $336,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Itau Unibanco Holding S.A. acquired a new stake in shares of Natera during the second quarter worth $28,000. Quarry LP grew its position in shares of Natera by 148.4% during the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after buying an additional 190 shares during the last quarter. GAMMA Investing LLC raised its stake in Natera by 50.0% during the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after acquiring an additional 108 shares during the period. Tobam bought a new position in Natera in the second quarter worth about $74,000. Finally, DekaBank Deutsche Girozentrale acquired a new position in Natera in the first quarter valued at approximately $83,000. 99.90% of the stock is currently owned by institutional investors.

Insider Activity at Natera

In other Natera news, CEO Steven Leonard Chapman sold 4,523 shares of Natera stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $130.40, for a total value of $589,799.20. Following the transaction, the chief executive officer now owns 191,163 shares in the company, valued at approximately $24,927,655.20. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, CEO Steven Leonard Chapman sold 4,523 shares of the stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $130.40, for a total value of $589,799.20. Following the completion of the transaction, the chief executive officer now owns 191,163 shares in the company, valued at $24,927,655.20. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Michael Burkes Brophy sold 1,866 shares of the business’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $99.65, for a total value of $185,946.90. Following the sale, the chief financial officer now owns 71,955 shares in the company, valued at approximately $7,170,315.75. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 50,765 shares of company stock valued at $6,016,700 over the last ninety days. Insiders own 7.60% of the company’s stock.

Natera Stock Up 0.0 %

NTRA opened at $122.40 on Friday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.01 and a current ratio of 4.14. The company has a market capitalization of $15.03 billion, a PE ratio of -39.23 and a beta of 1.53. The stock’s fifty day moving average is $123.30 and its 200-day moving average is $110.49. Natera, Inc. has a one year low of $36.90 and a one year high of $133.54.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.39. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The firm had revenue of $413.35 million for the quarter, compared to analysts’ expectations of $343.00 million. During the same period in the previous year, the business earned ($0.97) earnings per share. Natera’s revenue for the quarter was up 58.1% compared to the same quarter last year. On average, equities analysts predict that Natera, Inc. will post -1.96 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on NTRA shares. TD Cowen increased their price target on Natera from $137.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. BTIG Research raised their target price on Natera from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Friday, August 9th. StockNews.com upgraded shares of Natera from a “sell” rating to a “hold” rating in a research report on Thursday. Leerink Partners lifted their price objective on shares of Natera from $140.00 to $150.00 and gave the company an “outperform” rating in a research report on Thursday. Finally, Piper Sandler reissued an “overweight” rating and set a $150.00 target price on shares of Natera in a research note on Friday, September 13th. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, Natera currently has an average rating of “Moderate Buy” and a consensus price target of $124.44.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.